Nirsevimab, a long-acting monoclonal antibody targeting site Ø of the fusion (F) protein of the respiratory syncytial virus (RSV), was approved by the European Medicines Agency and the US Food and Drug Administration for the prevention of RSV infection...
SARS-CoV-2 infections were generally mild, but not increasingly so, along the evolution of omicron subvariants in this highly vaccinated population. About a third of participants with symptomatic infections reported that the symptoms severely affected ...
In The Lancet Infectious Diseases, Yawei Wang and colleagues reported the symptom characteristics of SARS-CoV-2 infections detected through regular self-screening of more than 10 000 people randomly selected from 18 regions in Hong Kong during a period...
This study is, to the best of our knowledge, the largest genotypic and phenotypic surveillance study of nirsevimab breakthrough infections to date. Nirsevimab breakthrough variants remain very rare despite the drug's widespread use. The detection of re...
In this emulated trial of adult patients with invasive GAS infections treated with β-lactam, linezolid appeared non-inferior to clindamycin suggesting linezolid as an alternative for adjunctive antitoxin therapy.
Streptococcus pyogenes, or group A streptococcus, remains a major global pathogen, responsible for a wide spectrum of diseases ranging from pharyngitis to severe invasive group A streptococcus (iGAS) infections.1 Central to the virulence of S pyogenes ...
Respiratory syncytial virus (RSV) is responsible for substantial morbidity and mortality in young children (
Viral times: reflections on the COVID-19 and HIV pandemics explores how the COVID-19 pandemic can shape our understanding of the HIV pandemic, and vice versa. The book is a compilation of 16 papers written by 28 authors, and includes case studies from ...
The COVID-19 pandemic has reshaped our understanding of coronaviruses. Although overshadowed by SARS-CoV-2, MERS-CoV still poses a public health threat. Cases were sporadic after 2019, with a case–fatality rate of 36%, but the death of all four reporte...
Hsu Y-C, Chen C-Y, Chang I-W, et al. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, paral...
MVA-MERS-S was safe and immunogenic in individuals with previous and concurrent SARS-CoV-2 exposure. The second vaccination with the 108 PFU dose of MVA-MERS-S elicited a stronger humoral immune response when administered 56 days after the first dose t...
These phase 3 efficacy and safety data provide support for aztreonam–avibactam as a potential therapeutic option for complicated intra-abdominal infection or HAP–VAP caused by Gram-negative bacteria.
Metallo-β-lactamase enzymes, named because of the presence of one or two zinc ions at the catalytic site, are responsible for β-lactam antibiotic hydrolysis and are increasing in prevalence worldwide.1 Despite the increase in antibiotic development ove...
Human African trypanosomiasis is a neglected tropical disease that is usually fatal without treatment. WHO has revised its rhodesiense human African trypanosomiasis treatment guidelines on the basis of an independent systematic literature review and fo...
COVID-19 is no longer a global pandemic but remains a public health problem and new vaccine formulations are still being developed to target newly emerging variants.1 Current guidelines recommend annual vaccination for all people older than 50 years an...
Almost 18 months on from WHO declaring that COVID-19 no longer constitutes a global health emergency, governments internationally are working to evaluate their response to the pandemic and identify where improvements could be made. COVID-19: confrontin...